Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-023595
Filing Date
2025-02-19
Accepted
2025-02-19 20:19:36
Documents
1
Period of Report
2025-02-14

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 5818
  Complete submission text file 0000950170-25-023595.txt   7289
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Issuer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O RAYZEBIO, INC. 5505 MOREHOUSE DRIVE, SUITE 300 SAN DIEGO CA 92121
Business Address
Kush Arvind (Reporting) CIK: 0001986806 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39676 | Film No.: 25642822